Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bloomberg Natural Gas ETF vs DexCom, Inc. — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $20.87, while DexCom, Inc. trades at $90.3 (market cap $33.79B). The key difference: DexCom, Inc. is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | DXCM | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $87.24 | $89.53 |
52-Week Low | $18.74 | $54.84 |
Market Cap | — | $33.79B |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $21.085, up 1.81% in the last 24 hours, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights U.S. natural gas futures stability amid weather-driven demand shifts. The company, Beyond Oil Ltd., focuses on food-tech innovations to reduce health risks in fried foods, with recent corporate actions including a 1:2 stock split effective May 28, 2026.
The outlook for BOIL is cautious due to bearish technical trends and reliance on natural gas market volatility. Investment opportunities hinge on energy sector demand and company-specific growth in food-tech, while risks include commodity price swings and execution challenges in scaling innovations.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
